HOUSTON & LEIDEN, The Netherlands & BASEL, Switzerland--(BUSINESS WIRE)--Stem Cell Innovations, Inc. (OTCBB: SCLL) announced today that the Company has started to validate a set of compounds that Circomed AG develops for certain cardiovascular indications. Financial details of this fee-for-service collaboration were not disclosed.
